ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.

J Immunother Cancer · 2020 · PMC7254123 · PMID 32461345

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

AZD6738 increased the numbers of TIL CD8 + T cells in triple therapy compared with that of in radioimmunotherapy, but the difference did not reach statistical significance.

also in 111,027 other papers

a decreasing trendno p-value reported

Moreover, compared with radioimmunotherapy (radiotherapy plus anti-PD-L1 (Programmed death ligand 1)), the addition of AZD6738 boosted the infiltration, increased cell proliferation, enhanced interferon (IFN)-γ production ability of TIL (tumor-infiltrating lymphocyte) CD8 + T cells, and caused a decreasing trend in the number of TIL Tregs and exhausted T cells in mice xenografts.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.